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Huntington’s disease (HD) is a genetic neurodegenerative disorder
characterized by motor, cognitive and psychiatric disturbances, and yet
there is no disease-specific patient-reported health-related quality of life
outcome measure for patients. Our aim was to develop and validate such
an instrument, i.e. the Huntington’s Disease health-related Quality of Life
questionnaire (HDQoL), to capture the true impact of living with this
disease. Semi-structured interviews were conducted with the full spectrum
of people living with HD, to form a pool of items, which were then
examined in a larger sample prior to data-driven item reduction. We
provide the statistical basis for the extraction of three different sets of
scales from the HDQoL, and present validation and psychometric data on
these scales using a sample of 152 participants living with HD. These new
patient-derived scales provide promising patient-reported outcome
measures for HD.
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The concept of health-related quality of life or the
impact of health problems on personal well-being and
life satisfaction (1) is particularly pertinent in neu-
rodegenerative disorders where there is no known
treatment to effectively modify the relentless progres-
sion of disease. Huntington’s disease (HD) is a fully
penetrant neurodegenerative disorder characterized by
motor, cognitive and psychiatric disturbances that usu-
ally occur in mid-life (2). This multifaceted disorder
begins insidiously and has a protracted course of up to
approximately two decades. The all-encompassing mul-
tidimensionality of the quality of life concept makes it
particularly relevant in chronic and degenerative disease
(3, 4) such as HD. Therefore health-related quality of
life is an important patient-reported outcome measure
that will provide information on patients’ personal
everyday experiences. Due to the genetic basis and
complex constellation of signs and symptoms of HD,
the subsequent multidimensional impact on patients is
great, and so it is important that a disease-specific mea-
sure is developed in order to fully capture the impact
of living with HD. Data from our studies (5, 6) and
others (7, 8) provide indications that generic scales
are unlikely to convey the true impact of living with
all aspects of HD, particularly the many non-physical
aspects of this neurodegenerative disease.
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The measurement of patient-reported outcomes is
increasingly important in clinical trials because it
provides the patients’ point-of-view which reflects the
overall net impact of any change or intervention; it takes
into account adverse-effect profiles that differentially
affect the various facets of disease, function and qual-
ity of life as experienced by patients from their unique
perspective.
In this study, we report on the development and
validation of the first patient-derived disease-specific
health-related quality of life scale for HD that aims
to adequately capture and measure the reported impact
on everyday life in this population. This new disease-
specific HD instrument, the Huntington’s Disease
health-related Quality of Life questionnaire (HDQoL),
will provide validated patient-reported outcome mea-
sures suitable for capturing health-related quality of life
in a way that is pertinent to this population.
Methods and results
Development of the HDQoL
Item generation from qualitative interviews
Semi-structured interviews were conducted in England
with 31 people living with HD, from pre-symptomatic
individuals to late-stage HD. Pre-symptomatic individ-
uals were included since psychosocial and quality of
life issues are relevant to this subgroup as well (9).
Interview questions were developed after a review of
literature, and included open-ended and specific probe
questions which addressed the health-related quality of
life definition adopted (emotional well-being, spiritu-
ality, sexuality, social functioning, family life, occu-
pational functioning, communication, eating, functional
ability, physical status, treatment satisfaction, self-
esteem, body image, future orientation, global ratings
of health and life satisfaction (10)). These face-to-face
interviews were audio-recorded, transcribed and ana-
lyzed to identify points generated by participants, which
then formed the basis for an initial pool of 81 items.
Ethical approval for the project was obtained from the
University of Reading Research Ethics Committee.
Item selection and questionnaire refinement
Feedback on these initial items was sought from a wider
pool of people living with HD to aid data-driven item
selection. Where necessary, these items were translated
by two appropriately bilingual members of the Euro-
pean Huntington’s Disease Network Quality of Life
Working Group and/or their associates. The disease
staging of patients was inferred via self-report responses
to questions concerning functional ability (11). Feed-
back on these initial items was obtained from 281 peo-
ple living with different levels of HD severity, including
at-risk individuals with HD family history but have not
undergone genetic testing, and pre-symptomatic indi-
viduals who were gene-positive carriers with no clinical
motor signs of HD. Each HD severity subgroup had
over 27 participants. Participants were from 12 different
countries, i.e. England (34.3%), Canada (20%), Spain
(9.8%), Scotland (9.5%), Belgium (8.3%), Norway
(5.7%), Germany (4.4%), Switzerland (2.2%), Portugal
(1.9%), Italy (1.6%), France (1.3%) and Ireland (0.6%).
Participants indicated how frequently they experi-
enced difficulty with each item as a result of HD, and
also how important each item was for their quality of
life. Items with low importance scores, high omission
rates or ambiguous content were eliminated. Item fre-
quency scores of the remaining items were then exam-
ined using Rasch analysis; items located at a similar
point on the logit scale were weighed against each other
on semantic content, coverage and uniqueness. Analy-
ses of variance procedures were also used to examine
items in terms of disease severity stages.
Validation of the HDQoL
The streamlined 40-item HDQoL questionnaire was
edited and reworded to enhance clarity. The HDQoL
was then pre-tested on a group of 20 participants from
pre-symptomatic to late-stage disease and reviewed in
the light of their feedback. The mean questionnaire
completion time of the questionnaire, across all disease
stages, was 22 min; all participants indicated that others
in their position would be positively predisposed to
completing this questionnaire, with 65% indicating it
would be acceptable, and 35% highly acceptable.
Following this pre-testing, the revised HDQoL (avail-
able from the corresponding author), two generic health
questionnaires, i.e. EuroQoL (EQ-5D) and SF-12v2,
and a demographic information sheet with self-report
on questions concerning functional ability (11) were
posted to the Huntington’s Disease Association United
Kingdom members. Since membership was not fully
updated and also did not distinguish between personal
and professional members, a meaningful response rate
could not be determined. Nevertheless, of the 261 ques-
tionnaires returned, 108 (41.38%) people decided not to
participate in the study due to miscellaneous personal
reasons, with fewer than 5% citing questionnaire dif-
ficulty. There were 152 completed questionnaire sets
(Table 1) and 102 participants indicated that they would
like to be contacted for the retest study 4–6 weeks
later, where the same questionnaires were resent to
participants, to establish test–retest reliability amongst
participants with no change in health-related quality of
life. Participants were instructed to complete the ques-
tionnaire from their own perspective, even if they might
require physical assistance in filling the forms.
Since one of the aims of this study was to provide
suitable health-related quality of life measures for this
population, we recognize that the type of measure suit-
able varies depending on the purpose of investigation.
We therefore provide the statistical basis for the extrac-
tion of three different sets of scales and their corre-
sponding psychometric properties, based on (i) Primary
Scales from a robust core triad of factors underlying
health-related quality of life, (ii) Specific Scales from
a more detailed profile of six clinically meaningful
dimensions, and finally (iii) a Summary Scale.
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Table 1. Key demographic details of the validation sample
No. of participants
(N = 152)
Self-reported HD stage
At risk 25
Pre-symptomatic gene positive 29
Stage 1 13
Stage 2 13
Stage 3 15
Stage 4 39
Stage 5 16
Information missing 2
Sex
Male 52
Female 100
Age group
Lowest to 44 35
44–64 85
65 to Highest 32
Marital status
Married or living with a partner 104
Divorced or separated 23
Single 19
Widowed 5
Information missing 1
Years of equivalent full-time education
0–6 years 4
7–12 years 54
13 to highest 63
Information missing 31
HD, Huntington’s disease.
Three Primary Scales
Following a principal component analysis (PCA,
oblimin rotation) of 112 participants with a complete
and unimputed dataset of the HDQoL, stringent parallel
analysis was conducted to identify three robust primary
factors with eigenvalues greater than factors derived
from the randomly generated parallel dummy datasets.
A forced three factor solution (Table 2) showed mini-
mal cross-loading and identified the following primary
factors, i.e. (i) Primary Physical and Cognitive (PPC),
(ii) Primary Emotions and Self (PES), and (iii) Primary
Services (PSR).
These three primary factors were then subjected to
Rasch analysis (RUMM2020) to test the unidimen-
sionality of these subscales in a manner less con-
strained by the limitations and assumptions of clas-
sical test theory. Initially, the three primary scales
showed unsatisfactory residual mean values, and sig-
nificant chi-squared item–trait interactions (p < 0.005)
indicating poor model fit. Following rescoring and
the reordering of thresholds, the PSR scale achieved
model fit; three items (weight, everyday memory, and
role in family) and two items (sleep and HD fam-
ily worry) were removed from the PPC and the PES
scales respectively. These adjusted and rescored pri-
mary scales also met the assumption of local indepen-
dence, demonstrating three unidimensional scales, and
no retained item showed differential item functioning
Table 2. Three Primary Scales: factor loadings for the HDQoL
Factor loading (Primary Scales)
Items
Physical and
Cognitive
Emotions
and Self Services
7. Dressing 0.95 — —
3. Walking 0.94 — —
8. Swallowing 0.93 — —
9. Eating 0.90 — —
4. Jobs around the house 0.87 — —
6. Hobby 0.87 — —
21. Remember date 0.81 — —
19. Organize day 0.81 — —
10. Operate television 0.79 — —
27. Independence 0.79 — —
2. Balance 0.77 — —
14. Slow 0.77 — —
13. Multitask 0.75 — —
1. Carrying things 0.72 — —
16. Concentration 0.71 (0.36) —
5. Weight 0.71 — —
18. Everyday memory 0.69 (0.33) —
20. Follow conversation 0.64 (0.34) —
15. Use words 0.64 (0.34) —
17. Decision making 0.62 (0.41) —
31. Role in family 0.54 (0.31) —
25. Motivation (0.48) 0.48 —
11. Tired (0.46) 0.42 —
12. Sleep (0.39) 0.38 —
24. Hope — 0.81 —
29. Low mood — 0.76 —
23. HD worry — 0.75 —
32. Financial concerns — 0.71 —
22. HD family worry — 0.68 —
33. Irritated — 0.64 —
34. Temper — 0.62 (0.34)
30. Personal wishes (0.38) 0.53 —
26. Get on with life (0.49) 0.53 —
28. Confidence (0.48) 0.52 —
36. Other’s attitude to HD — 0.51 —
35. Socialize — 0.46 —
40. Information on HD — — 0.87
38. Services for HD — — 0.84
39. Management of HD — — 0.83
37. Support — — 0.45
HD, Huntington’s disease; HDQoL, Huntington’s disease health-
related quality of life questionnaire.
for gender. All scales also showed good to moderate tar-
geting of scale to sample (average mean person location
value for PPC = −1.05, PES = −0.20, PSR = −1.20),
scale reliability was high (person separation index for
PPC = 0.97, PES = 0.91, PSR = 0.78, as was internal
consistency, i.e. Cronbach’s alpha for PPC = 0.96,
PES = 0.89, PSR = 0.76).
Six Specific Scales
From the previous PCA (oblimin rotation) of the
HDQoL, the commonly used Kaiser’s criterion for fac-
tor retention of eigenvalues greater than 1 and Cattell’s
scree test were used to identify six specific factors, that
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were meaningful and clinically relevant (Table 3), i.e.
(i) Specific Cognitive (SCG), (ii) Specific Hopes and
Worries (SHW), (iii) Specific Services (SSR), (iv) Spe-
cific Physical and Functional (SPF), (v) Specific Mood
State (SMS), and (vi) Specific Self and Vitality (SSV).
Following Rasch analysis, all scales were rescored to
correct for disordered thresholds and to improve model
fit. Items still showing deviation from the model were
eliminated from the SCG scale (i.e. personal wishes)
and SPF scale (i.e. weight). Retained items did not
show differential item functioning for gender. These six
adjusted and rescored specific scales met the assump-
tion of local independence and were unidimensional.
All scales also showed good to moderate targeting of
scale to sample (average mean person location value for
SCG = −0.42, SHW = −0.25, SSR = −0.81, SPF =
−1.23, SMS = −0.79, SSV = −0.65); scale reliabil-
ity was high (person separation index for SCG = 0.97,
SHW = 0.77, SSR = 0.82, SPF = 0.94, SMS = 0.86,
SSV = 0.88, as was internal consistency, i.e. Cron-
bach’s alpha for SCG = 0.94, SHW = 0.72, SSR =
0.77, SPF = 0.91, SMS = 0.78, SSV = 0.78).
Summary scale
Rasch analysis was used to identify global health-
related quality of life from the 40 patient-derived items.
The initial model fit was examined and the sources
Table 3. Six Specific Scales: factor loadings for the HDQoL
Factor loadings (Specific Scales)
Items Cognitive
Hopes and
Worries Services
Physical and
Functional Mood State
Self and
Vitality
18. Everyday memory 0.88 — — — — —
19. Organize day 0.78 — — — — —
21. Remember date 0.73 — — — — —
16. Concentration 0.72 — — — — —
13. Multitask 0.71 — — — — —
14. Slow 0.70 — — — — —
20. Follow conversation 0.69 — — — — —
15. Use words 0.65 — — — — —
17. Decision making 0.62 — — — — —
6. Hobby (0.56) — — 0.39 — —
30. Personal wishes 0.45 — — — (−0.37) —
28. Confidence (0.44) — — — −0.32 —
12. Sleep (0.32) (0.32) — — — 0.31
22. HD family worry — 0.85 — — — —
23. HD worry — 0.76 — — — —
24. Hope — 0.69 — — — —
32. Financial concerns — 0.58 — — — —
36. Other’s attitude to HD — 0.53 — — — —
38. Services for HD — — 0.88 — — —
39. Management of HD — — 0.87 — — —
40. Information on HD — — 0.87 — — —
37. Support — — (0.51) — — 0.48
5. Weight — — — 0.89 — —
9. Eating — — — 0.82 — —
7. Dressing — — — 0.78 — —
3. Walking — — — 0.72 — —
10. Operate television — — — 0.71 — —
8. Swallowing — — — 0.71 — —
1. Carrying things — — — 0.61 — —
2. Balance (0.34) — — 0.51 — —
27. Independence (0.32) — — 0.48 — —
4. Jobs around the house (0.46) — — 0.48 — —
33. Irritated — — — — −0.83 —
34. Temper — — — — −0.79 —
29. Low mood — — — — −0.49 (0.38)
35. Socialize — — — — −0.43 —
26. Get on with life (0.34) — — — — 0.52
31. Role in family — — — — — 0.43
25. Motivation (0.34) — — — −0.34 0.40
11. Tired (0.31) — — — — 0.39
HD, Huntington’s disease; HDQoL, Huntington’s disease health-related quality of life questionnaire.
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of model misfit addressed by rescoring and ordering
thresholds, eliminating items (i.e. 1, 2, 4–6, 8, 12–17,
23, 26, 27, 30, 34, 36, 40 from Table 2) showing devi-
ation from the model expectations or differential item
functioning. For the remaining 21 items, the summary
scale showed good targeting of scale to sample (average
mean person location value = −0.69); scale reliability
was high (person separation index = 0.92, as was inter-
nal consistency, i.e. Cronbach’s alpha = 0.89).
Psychometric properties of the HDQoL scales
The acceptability and psychometric properties of the
three sets of scales (Primary, Specific and Summary)
derived from the HDQoL are presented in Table 4. Item
scores in each scale were summed and transformed into
a scale ranging from 0 to 100, where higher scores
indicate better health-related quality of life.
All three sets of scales showed good stability
over repeated testing (test–retest reliability ≥0.7), and
good scale unidimensionality (Cronbach’s alpha ≥0.7).
Scale acceptability was generally good with minimal
skewness (approximately between −1 and 1) and
floor/ceiling effect (≤20%) for most scales. Since pre-
symptomatic and at-risk participants were included in
the sample, ceiling effects were therefore more apparent
in the Primary Physical and Cognitive scale, and for
both the Specific Physical and Functional as well as
Specific Cognitive scales; however, there was no ceiling
effect in the same sample for Primary and Specific
scales that related to emotions and mood. The Services
scale of both the Primary and Specific scales showed
ceiling effect; which may naturally reflect the biased
sample population who were recruited to this study
via the HD association, and may therefore have been
already particularly aware and satisfied with getting
access to information, services and sources of support.
Construct validity was established by examining the
three sets of scales with respect to two well-known
generic instruments, the SF-12v2 and EQ-5D. Table 5
shows the expected pattern of correlations with each set
of HDQoL-derived scales.
Discussion
Using a data-driven approach, this article presents
a novel disease-specific patient-reported health-related
quality of life outcome measure for HD, which is called
the Huntington’s Disease health-related Quality of Life
questionnaire (i.e., HDQoL). Both traditional and Rasch
analyses were used to derive three sets of scales derived
from this instrument, i.e. (i) three robust Primary Scales
that represent core factors underlying health-related
quality of life in HD, (ii) six Specific Scales that
represent a clinically meaningful HD-specific profile
of pertinent aspects of health-related quality of life,
and (iii) a Summary Scale. The administration of the
HDQoL in the target user group, using a substantial and
diverse sample of HD patients, allowed its performance
to be evaluated to determine its suitability as a
measure of health-related quality of life. The HDQoL
showed good test–retest reliability, construct validity,
and scale acceptability. Its scales are appropriately
unidimensional, and have acceptable measurement and
psychometric properties given the broad spectrum of
patients and participants in this sample. The three
Primary Scales and single Summary Scale are robust
and promising outcome measures for evaluating health-
related quality of life in HD patients, and the six
Specific Scales offer the potential for examining more
detailed and clinically meaningful aspects of quality of
life in this population. Importantly, the patient-derived
HDQoL was found to be acceptable to people living
with HD in terms of its content and administration time;
two thirds of this diverse spectrum of patients, including
late-stage HD, completed this 40-item questionnaire in
less than the mean completion time of 22 min.
Our sample comprised more women than men, and
although this is unlikely to have significantly influenced
the results given what is known of HD and also
Table 4. Psychometric properties of the three sets of scales derived from the HDQoL
Sets of scales derived
from the HDQoL
Mean
score
Standard
deviation
Floor effect
(0–10%)
Ceiling effect
(90–100%) Skewness
Cronbach’s
alpha
Test–retest
reliability
Three Primary Scales
Physical and Cognitive 63.4 32.3 7.9 30.9 −0.4 0.9 0.8
Emotions and Self 53.2 27.2 7.2 10.5 −0.1 0.9 0.8
Services 78.7 28.9 3.9 50.0 −1.3 0.8 0.7
Six Specific Scales
Cognitive 55.7 33.2 12.5 27.0 −0.1 0.9 0.8
Hopes and Worries 52.9 27.5 5.9 11.8 −0.1 0.7 0.7
Services 73.4 32.9 7.9 50.0 −1.0 0.8 0.7
Physical and Functional 68.4 32.0 7.2 36.2 −0.6 0.7 0.8
Mood State 61.7 27.8 7.2 20.4 −0.5 0.8 0.7
Self and Vitality 60.0 26.3 5.3 12.5 −0.5 0.8 0.7
One Summary Scale
Summary Scale 61.0 24.8 4.6 16.4 −0.8 0.9 0.7
HDQoL, Huntington’s disease health-related quality of life questionnaire.
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Table 5. Convergent and discriminant validity of the three sets of scales derived from the HDQoL, the three primary scales, the six
specific scales and the single summary scale
Three Primary Scales Six Specific Scales Summary
Physical and
Cognitiveb
Emotions
and Selfb Servicesb Cognitiveb
Hopes and
Worriesb Servicesb
Physical and
Functionalb
Mood
Stateb
Self and
Vitalityb
Summary
Scaleb
EQ-5D
Mobilitya −0.7 −0.5 −0.3 −0.6 −0.3 −0.3 −0.7 −0.4 −0.5 −0.6
Selfcarea −0.8 −0.5 −0.3 −0.6 −0.4 −0.3 −0.8 −0.4 −0.5 −0.7
Activitya −0.8 −0.5 −0.4 −0.8 −0.3 −0.4 −0.8 −0.5 −0.6 −0.7
Paina −0.4 −0.4 −0.4 −0.4 −0.2 −0.4 −0.4 −0.4 −0.4 −0.4
Anxietya −0.4 −0.6 −0.2 −0.5 −0.5 −0.2 −0.3 −0.6 −0.5 −0.5
Index scoreb 0.8 0.7 0.5 0.7 0.5 0.5 0.8 0.6 0.7 0.8
VisAnalogb 0.7 0.5 0.4 0.6 0.3 0.3 0.6 0.4 0.6 0.6
SF12v12
Physicalb 0.8 0.4 0.3 0.7 0.2 0.3 0.8 0.3 0.5 0.6
Mentalb 0.5 0.8 0.4 0.6 0.6 0.3 0.4 0.7 0.7 0.7
HDQoL, Huntington’s disease health-related quality of life questionnaire.
aHigher score indicates lower quality of life/health status.
bHigher score indicates better quality of life/health status.
gender comparison in quality of life in Parkinson’s
disease (12), further work to replicate these results
in a larger sample is warranted. This will also allow
limitations of this study to be addressed, such as the
possible sample self-selection bias, and investigation
of other clinical variables including clinician rating
of patient severity rather than inference from self-
report. While a patient-reported measure of health-
related quality of life is necessarily subjective, it would
also be informative to examine proxy (e.g. carer)
ratings of patients’ health-related quality of life in
view of the cognitive impairment that is associated
with HD. Further work is also needed to examine
issues such as scale responsiveness and sensitivity to
placebo effects. These next steps will provide further
information regarding the instrument and its subscales,
and will be useful for future clinical applications.
In summary, the patient-derived HDQoL is a new
disease-specific questionnaire which provides appropri-
ate measures of health-related quality of life to capture
the true impact of HD across disease severity. The
HDQoL provides validated scales which are HD spe-
cific and therefore more likely to be sensitive than
generic scales. It allows the impact of interventions
to be appropriately and holistically evaluated from the
patients’ perspective, and will be valuable in promoting
more fully informed decision making in the manage-
ment of HD.
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